ReviewPediatric nephrology (Berlin, Germany)2026
Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hematuria has traditionally been considered a benign sign of glomerular injury, as reported in autosomal dominant type IV collagen-related nephropathy. However, growing clinical and experimental evidence suggests that it may be an active driver of kidney dysfunction. Persistent microscopic hematuria is associated with an increased risk of progression to kidney failure. Likewise, episodes of macroscopic hematuria, particularly in Immunoglobulin A nephropathy, can precipitate acute kidney injury and contribute to chronic impairment of kidney function. Glomerular bleeding may be associated with alterations in the glomerular filtration barrier, allowing erythrocyte leakage into the urinary space. At the molecular level, erythrocyte breakdown products, such as free hemoglobin and heme, induce oxidative stress and inflammation, exerting direct cytotoxic effects on kidney parenchymal cells. In this comprehensive review, we describe the prevalence of hematuria in pediatric patients, elucidate the cellular and molecular mechanisms by which hemoglobin and its heme derivatives promote kidney injury, evaluate the impact of hematuria on long-term kidney outcomes, and discuss emerging therapies against hematuria-induced nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.